Ocular Therapeutix, Inc (OCUL): Gross Profit
$45.38M
Year ended 2025-12-31
$45.35M
Trailing 12 months to 2026-06-30
-1.1%
3-year compound annual growth
+24.3%
5-year compound annual growth
+41.3%
10-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $45.38M | -21.9% | 2026-02-05, From 2025-01-01 |
| 2024-12-31 | $58.10M | +9.3% | 2026-02-05, From 2024-01-01 |
| 2023-12-31 | $53.16M | +13.2% | 2026-02-05, From 2023-01-01 |
| 2022-12-31 | $46.95M | +20.0% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $39.12M | +155.3% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $15.32M | +705.5% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $1.90M | +24.7% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $1.52M | +4.0% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $1.47M | +1.5% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $1.44M | +0.9% | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | $1.43M | +110.1% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $681.0K | n/a | 2017-03-10, From 2014-01-01 |
| No annual figure between 2012-12-31 and 2014-12-31. | |||
| 2012-12-31 | $3.0K | n/a | 2015-03-20, From 2012-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $45.38M | -21.9% |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | $47.68M | +47.5% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $5.56M | +43.2% |
| Nektar Therapeutics (NKTR) | 2024-12-31 | $67.74M | +20.2% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $36.82M | -19.7% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $25.99M | -34.5% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $37.85M | +21.0% |
| Journey Medical Corp (DERM) | 2025-12-31 | $40.31M | +17.7% |
| Nuvation Bio Inc. (NUVB) | 2024-12-31 | $795.0K | n/a |
Compare OCUL, AGIO, INBP, NKTR side by side · Screen every company in Pharmaceutical Preparations ↗